Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab with Single Agent Chemotherapy in Elderly Advanced NSCLC
NCT04754815Phase 2Withdrawn
- Sponsor
- Shirish M Gadgeel
- Start
- Apr 2021
- Primary completion
- Apr 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
01
Overview
A Phase 2 trial of pembrolizumab in non-small cell lung cancer (NSCLC), sponsored by Shirish M Gadgeel. Planned start Apr 2021; status: withdrawn.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04754815.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04754815.